Do analysts rate IRON or XBIT?

Disc Medicine currently has a consensus price target of $110.18, indicating a potential upside of 65.84%. Given Disc Medicine's stronger consensus rating and higher probable upside, equities analysts plainly believe Disc Medicine is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.77 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, IRON or XBIT?

Disc Medicine is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A XBiotech N/A N/A -$45.54M -$1.48 N/A

Is IRON or XBIT more profitable?

XBiotech's return on equity of -31.62% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% XBiotech N/A -31.62% -30.29%

Do analysts rate IVVD or XBIT?

Invivyd presently has a consensus price target of $8.00, indicating a potential upside of 775.94%. Given Invivyd's stronger consensus rating and higher probable upside, analysts plainly believe Invivyd is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IVVD or XBIT more profitable?

XBiotech has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. XBiotech's return on equity of -31.62% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -183.90% -59.73% -48.97% XBiotech N/A -31.62% -30.29%

Do analysts rate FHTX or XBIT?

Foghorn Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 224.07%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Foghorn Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, GALT or XBIT?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A XBiotech N/A N/A -$45.54M -$1.48 N/A

Is GALT or XBIT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat XBiotech's return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% XBiotech N/A -31.62% -30.29%

Do analysts recommend XBIT or ALEC?

Alector has a consensus target price of $3.63, indicating a potential upside of 88.80%. Given Alector's stronger consensus rating and higher possible upside, analysts clearly believe Alector is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13

Is XBIT or ALEC more profitable?

XBiotech has a net margin of 0.00% compared to Alector's net margin of -850.13%. XBiotech's return on equity of -31.62% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -31.62% -30.29% Alector -850.13% -531.03% -44.00%

XBiotech (XBIT) Competitors

$2.16 -0.02 (-0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$2.16 +0.00 (+0.23%)

As of 07:30 PM Eastern

Compare

XBIT vs. IRON, IVVD, FHTX, GALT, and ALEC

Should you buy XBiotech stock or one of its competitors? XBiotech's main competitors and comparable companies include Disc Medicine (IRON), Invivyd (IVVD), Foghorn Therapeutics (FHTX), Galectin Therapeutics (GALT), and Alector (ALEC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does XBiotech compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and XBiotech (NASDAQ:XBIT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

XBiotech's return on equity of -31.62% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
XBiotech	N/A	-31.62%	-30.29%

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Disc Medicine has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Disc Medicine is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

In the previous week, Disc Medicine had 3 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Disc Medicine and 1 mentions for XBiotech. Disc Medicine's average media sentiment score of 0.26 beat XBiotech's score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Disc Medicine	Neutral
XBiotech	Neutral

Disc Medicine currently has a consensus price target of $110.18, indicating a potential upside of 65.84%. Given Disc Medicine's stronger consensus rating and higher probable upside, equities analysts plainly believe Disc Medicine is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Disc Medicine beats XBiotech on 7 of the 13 factors compared between the two stocks.

How does XBiotech compare to Invivyd?

Invivyd (NASDAQ:IVVD) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Invivyd presently has a consensus price target of $8.00, indicating a potential upside of 775.94%. Given Invivyd's stronger consensus rating and higher probable upside, analysts plainly believe Invivyd is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 12.3% of Invivyd shares are owned by company insiders. Comparatively, 30.8% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

XBiotech has lower revenue, but higher earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	5.04	-$52.49M	-$0.33	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

In the previous week, Invivyd had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Invivyd and 1 mentions for XBiotech. Invivyd's average media sentiment score of 1.34 beat XBiotech's score of 0.00 indicating that Invivyd is being referred to more favorably in the media.

Company	Overall Sentiment
Invivyd	Positive
XBiotech	Neutral

Invivyd has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

XBiotech has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. XBiotech's return on equity of -31.62% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
XBiotech	N/A	-31.62%	-30.29%

Summary

Invivyd beats XBiotech on 8 of the 14 factors compared between the two stocks.

How does XBiotech compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

XBiotech has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
XBiotech	N/A	-31.62%	-30.29%

XBiotech has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	6.92	-$74.28M	-$0.98	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 1 articles in the media. Foghorn Therapeutics' average media sentiment score of 0.00 equaled XBiotech'saverage media sentiment score.

Company	Overall Sentiment
Foghorn Therapeutics	Neutral
XBiotech	Neutral

Foghorn Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by insiders. Comparatively, 30.8% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Foghorn Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 224.07%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Foghorn Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Foghorn Therapeutics beats XBiotech on 8 of the 12 factors compared between the two stocks.

How does XBiotech compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Galectin Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 30.8% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Galectin Therapeutics' return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
XBiotech	N/A	-31.62%	-30.29%

Galectin Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 177.78%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Galectin Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

In the previous week, Galectin Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Galectin Therapeutics and 1 mentions for XBiotech. Galectin Therapeutics' average media sentiment score of 0.44 beat XBiotech's score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Galectin Therapeutics	Neutral
XBiotech	Neutral

Summary

Galectin Therapeutics beats XBiotech on 9 of the 13 factors compared between the two stocks.

How does XBiotech compare to Alector?

XBiotech (NASDAQ:XBIT) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Alector has a consensus target price of $3.63, indicating a potential upside of 88.80%. Given Alector's stronger consensus rating and higher possible upside, analysts clearly believe Alector is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

XBiotech has a net margin of 0.00% compared to Alector's net margin of -850.13%. XBiotech's return on equity of -31.62% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Alector	-850.13%	-531.03%	-44.00%

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

XBiotech has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Alector has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

XBiotech has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Alector	$21.05M	10.18	-$142.93M	-$1.10	N/A

In the previous week, Alector had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Alector and 1 mentions for XBiotech. XBiotech's average media sentiment score of 0.00 equaled Alector'saverage media sentiment score.

Company	Overall Sentiment
XBiotech	Neutral
Alector	Neutral

Summary

XBiotech and Alector tied by winning 7 of the 14 factors compared between the two stocks.

Get XBiotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIT vs. The Competition

Export

Metric	XBiotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$66.46M	$3.92B	$7.26B	$13.10B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.46	14.07	274.98	25.77
Price / Sales	N/A	1,481.97	679.25	97.61
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.47	15.46	10.52	6.34
Net Income	-$45.54M	-$22.82M	$3.49B	$360.00M
7 Day Performance	-0.92%	-2.21%	-1.08%	-0.11%
1 Month Performance	-6.49%	-6.66%	-3.39%	-3.42%
1 Year Performance	-22.30%	30.99%	15.08%	5.46%

XBiotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIT XBiotech	0.2796 of 5 stars	$2.16 -0.9%	N/A	-25.1%	$66.46M	N/A	N/A	87
IRON Disc Medicine	2.3754 of 5 stars	$67.30 -2.4%	$109.55 +62.8%	+6.3%	$264.28M	N/A	N/A	165
IVVD Invivyd	3.5747 of 5 stars	$0.83 -6.9%	$8.00 +863.9%	-20.4%	$262.87M	$53.43M	N/A	122	Positive News Gap Up
FHTX Foghorn Therapeutics	1.7528 of 5 stars	$4.12 -5.5%	$11.43 +177.4%	-22.8%	$258.92M	$30.91M	N/A	106
GALT Galectin Therapeutics	1.83 of 5 stars	$3.73 -2.9%	$11.00 +194.9%	-15.8%	$252.89M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIT) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XBiotech (XBIT) Competitors

XBIT vs. IRON, IVVD, FHTX, GALT, and ALEC

How does XBiotech compare to Disc Medicine?

Summary

How does XBiotech compare to Invivyd?

Summary

How does XBiotech compare to Foghorn Therapeutics?

Summary

How does XBiotech compare to Galectin Therapeutics?

Summary

How does XBiotech compare to Alector?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XBiotech (XBIT) Competitors

XBIT vs. IRON, IVVD, FHTX, GALT, and ALEC

How does XBiotech compare to Disc Medicine?

Is IRON or XBIT more profitable?

Do insiders and institutionals believe in IRON or XBIT?

Which has more volatility and risk, IRON or XBIT?

Which has preferable earnings & valuation, IRON or XBIT?

Does the media prefer IRON or XBIT?

Do analysts rate IRON or XBIT?

Summary

How does XBiotech compare to Invivyd?

Do analysts rate IVVD or XBIT?

Do institutionals and insiders believe in IVVD or XBIT?

Which has preferable valuation and earnings, IVVD or XBIT?

Does the media refer more to IVVD or XBIT?

Which has more risk and volatility, IVVD or XBIT?

Is IVVD or XBIT more profitable?

Summary

How does XBiotech compare to Foghorn Therapeutics?

Is FHTX or XBIT more profitable?

Which has stronger earnings and valuation, FHTX or XBIT?

Does the media refer more to FHTX or XBIT?

Which has more risk and volatility, FHTX or XBIT?

Do institutionals and insiders hold more shares of FHTX or XBIT?

Do analysts rate FHTX or XBIT?

Summary

How does XBiotech compare to Galectin Therapeutics?

Which has higher valuation & earnings, GALT or XBIT?

Do institutionals & insiders hold more shares of GALT or XBIT?

Is GALT or XBIT more profitable?

Do analysts prefer GALT or XBIT?

Which has more risk and volatility, GALT or XBIT?

Does the media prefer GALT or XBIT?

Summary

How does XBiotech compare to Alector?

Do analysts recommend XBIT or ALEC?

Is XBIT or ALEC more profitable?

Do insiders & institutionals believe in XBIT or ALEC?

Which has more volatility & risk, XBIT or ALEC?

Which has stronger valuation & earnings, XBIT or ALEC?

Does the media favor XBIT or ALEC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools